ArticleAmerican journal of cancer research2025
Lower MMP12 expression is likely to contribute to better effect of postoperative adjuvant transarterial chemoembolization via reducing MEK/ERK signaling activity in patients with hepatocellular carcinoma.
Article in American journal of cancer research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hepatocellular carcinoma (HCC) frequently recurs after hepatectomy. Transarterial chemoembolization (TACE) is a common adjuvant therapy; however, reliable indicators of its efficacy remain limited. This study aimed to evaluate the clinical significance of matrix metallopeptidase 12 (MMP12) in HCC patients undergoing postoperative adjuvant TACE (PA-TACE) and to explore potential strategies to enhance the efficacy of PA-TACE. A retrospective analysis was conducted on 225 HCC patients who received TACE and were categorized into prophylactic and recurrence TACE groups. Clinical data including liver function, tumor characteristics, and imaging findings were collected. Tissue samples were subjected to MMP12 immunohistochemical staining, and patients were further stratified according to MMP12 expression levels. Univariate and multivariate Cox regression analyses were performed to identify risk factors, and a nomogram was constructed for prognostic evaluation. The role of MMP12 in TACE for HCC was examined using Western blotting, RT-qPCR, mass spectrometry, Transwell, wound-healing, and colony formation assays. Kaplan-Meier curves demonstrated significantly better survival in the low-MMP12-expression group. Microvascular infiltration, alpha-fetoprotein (AFP) levels, and MMP12 expression were identified as independent risk predictors for survival. The nomogram derived from these factors exhibited high predictive accuracy (area under the curve: 0.750-0.959) across multiple time points. In vitro experiments revealed that targeting MMP12 inhibited HCC cell invasion, migration, and colony formation by blocking the MEK/ERK signaling pathway. The MMP12 inhibitor GM6001 enhanced the therapeutic effects of TACE. In conclusion, MMP12 was identified as a key and independent prognostic biomarker for PA-TACE in HCC patients. The prognostic model integrating MMP12, AFP, and microvascular infiltration may help identify patients most likely to benefit from PA-TACE. Targeting MMP12 to block the MEK/ERK pathway and suppress HCC cell malignancy highlights its potential as a therapeutic target to improve PA-TACE efficacy.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.